The goal of this assay is to identify compounds that specifically reduce streptokinase expression without inhibiting cell growth. Active compounds from the primary screen were tested in 6-point, 3-fold dilution doses with starting concentration at 15 uM as follows. GAS UMAA2166 at OD600 equal to 0.015 were plated onto 384-well plates (Corning 3570) and incubated with test compounds in more ..
Target
| Sequence: streptokinase A precursor [Streptococcus pyogenes M1 GAS] Description ..   Protein Family: Staphylokinase/Streptokinase family Gene:SKA Related Protein 3D Structures |
BioActive Compounds: 773
Depositor Specified Assays
| AID | Name | Type | Probe | Comment |
|---|---|---|---|---|
| 1662 | MLPCN Streptokinase Expression Inhibition | screening | Primary HTS | |
| 1677 | Broad Institute MLPCN Streptokinase Expression Inhibition Project | summary | 3 | Project Summary |
| 1902 | Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promotor Activity | confirmatory | Retest at Dose | |
| 1900 | Luminescence Microorganism-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to SK(-)GAS Group A Streptococcus | confirmatory | Counter Screen | |
| 2470 | Absorbance Microorganism-Based Dose Response Followup to Identify Inhibitors of Streptokinase Expression. | confirmatory | ||
| 2477 | Luminescence Microorganism-Based Dose Response Followup to Identify Compounds Cytotoxic to Streptococcus. | confirmatory | ||
| 2137 | Absorbance Microorganism-Based Dose Response Followup to Identify Inhibitors of Streptokinase Expression | confirmatory | ||
| 2138 | Luminescence Microorganism-Based Dose Response Followup to Identify Compounds Cytotoxic to Streptococcus | confirmatory |
Description:
Keywords:
Group A streptococcus, GAS, streptokinase, expression, virulence, inhibition, dose response, EC50
Assay Overview:
The goal of this assay is to identify compounds that specifically reduce streptokinase expression without inhibiting cell growth. Active compounds from the primary screen were tested in 6-point, 3-fold dilution doses with starting concentration at 15 uM as follows. GAS UMAA2166 at OD600 equal to 0.015 were plated onto 384-well plates (Corning 3570) and incubated with test compounds in Todd-Hewitt Broth medium supplemented with 100 ug/ml of streptomycin for 6 hours before cells were pelleted. Supernatant of cells was removed and tested for SK activity by measuring activation of plasminogen in an absorbance-based assay as described in the Protocol section. Cell pellets were assayed for viability by BacTiterGlo reagent (Promega G8233). Normalized SK activity values were generated by dividing values of SK activity by the values of viability reading, and used to generate IC50 values as described in the Data Analysis/Comments section. Results for viability alone are reported in a separate assay. Selectivity is determined by comparing IC50 values of reduction of normalized SK activity and IC50 values of reduction of viability.
Expected Outcome:
The project is looking for compounds that selectively reduce expression of SK activity without inhibiting cell growth.
Group A streptococcus, GAS, streptokinase, expression, virulence, inhibition, dose response, EC50
Assay Overview:
The goal of this assay is to identify compounds that specifically reduce streptokinase expression without inhibiting cell growth. Active compounds from the primary screen were tested in 6-point, 3-fold dilution doses with starting concentration at 15 uM as follows. GAS UMAA2166 at OD600 equal to 0.015 were plated onto 384-well plates (Corning 3570) and incubated with test compounds in Todd-Hewitt Broth medium supplemented with 100 ug/ml of streptomycin for 6 hours before cells were pelleted. Supernatant of cells was removed and tested for SK activity by measuring activation of plasminogen in an absorbance-based assay as described in the Protocol section. Cell pellets were assayed for viability by BacTiterGlo reagent (Promega G8233). Normalized SK activity values were generated by dividing values of SK activity by the values of viability reading, and used to generate IC50 values as described in the Data Analysis/Comments section. Results for viability alone are reported in a separate assay. Selectivity is determined by comparing IC50 values of reduction of normalized SK activity and IC50 values of reduction of viability.
Expected Outcome:
The project is looking for compounds that selectively reduce expression of SK activity without inhibiting cell growth.
Protocol
Day 1 Streak out UMAA 2616 for colonies on THY/S (THY with streptomycin 100 μg/mL) plate; 37'C O/N
Day 2 Grow an overnight culture in THY/S from a single colony, 37oC O/N
Day 3 In the morning, dilute 1:20 of the O/N culture into fresh THY/S in flask. Monitor OD600 until it reaches 0.6-0.8 (between 3-5 hrs).
Dilute the 0.8OD Culture down to OD 0.038 into cold (4'C) THY/S; stir at 4'C O/N
Day 4 Dispense assay plates (Corning 3570) at 30ul/well of THY/S with Combi (Thermo)
Pin Compounds (100 nL) using Cybi-Well (CyBio)
Seed cells (warmed up to RT) onto the pinned plates at 20ul/well with Combi
37'C for 6 hrs in Liconic incubator
Pellet cells at 3000 rpm
Transfer 2 x 10 uL/well supernatant to clear plates (Nunc 242757) for assay with Cybi-Well Vario (CyBio), store at -20'C.
Cool the culture plates to RT for 30 minutes
Add 50 uL/well of 1/2x BacTiterGlo (Promega G8233)
RT 10 minutes, Read for luminescence
SK activity is measured as follows:
Add 50 uL/well of SK assay solution (5 uL of human plasma, 1.2 uL of 4.2mg/ml S2403, 43.8 uL of PBS) to the 10 uL/well supernatant (thawed and warmed up to RT) in clear SK assay plates with Combi
Read OD405 at 0 hrs
37'C for 2.5 hrs
Read OD405
37'C for 2.5 hrs
Read OD405
Day 2 Grow an overnight culture in THY/S from a single colony, 37oC O/N
Day 3 In the morning, dilute 1:20 of the O/N culture into fresh THY/S in flask. Monitor OD600 until it reaches 0.6-0.8 (between 3-5 hrs).
Dilute the 0.8OD Culture down to OD 0.038 into cold (4'C) THY/S; stir at 4'C O/N
Day 4 Dispense assay plates (Corning 3570) at 30ul/well of THY/S with Combi (Thermo)
Pin Compounds (100 nL) using Cybi-Well (CyBio)
Seed cells (warmed up to RT) onto the pinned plates at 20ul/well with Combi
37'C for 6 hrs in Liconic incubator
Pellet cells at 3000 rpm
Transfer 2 x 10 uL/well supernatant to clear plates (Nunc 242757) for assay with Cybi-Well Vario (CyBio), store at -20'C.
Cool the culture plates to RT for 30 minutes
Add 50 uL/well of 1/2x BacTiterGlo (Promega G8233)
RT 10 minutes, Read for luminescence
SK activity is measured as follows:
Add 50 uL/well of SK assay solution (5 uL of human plasma, 1.2 uL of 4.2mg/ml S2403, 43.8 uL of PBS) to the 10 uL/well supernatant (thawed and warmed up to RT) in clear SK assay plates with Combi
Read OD405 at 0 hrs
37'C for 2.5 hrs
Read OD405
37'C for 2.5 hrs
Read OD405
Comment
A. Normalized SK expression values were derived by
1) subtracting intial OD405 values at time 0 hrs from final OD405 values at time 2.5 hrs, to determine the change in absorbance (deltaOD405);
2) dividing this subtracted value by the luminescence (RLU) reading to normalize for cell number variation, resulting in a normalized SK expression value: deltaOD405/RLU
3) normalized SK expression values were background subtracted using the median of the 32 negative controls wells on the same plate and scaled using the median value of the 32 positive control wells located on two separate control plates in the same run.
B. IC50 values were calculated based on the normalized, scaled SK expression values using the Smart Fit strategy of Genedata Screener Condoseo (v6.0.1). IC50 values were extrapolated up to 1 log over the highest tested concentration.
PUBCHEM_ACTIVITY_SCORE:
Inactive compounds = 0
Active compounds = -10*Log(IC50)
PUBCHEM_ACTIVITY_OUTCOME:
Activity_Outcome = 1 (inactive)
IC50 > 1 log over the highest tested concentration
Activity_Outcome = 2 (active)
IC50 <= 1 log over the highest tested concentration
1) subtracting intial OD405 values at time 0 hrs from final OD405 values at time 2.5 hrs, to determine the change in absorbance (deltaOD405);
2) dividing this subtracted value by the luminescence (RLU) reading to normalize for cell number variation, resulting in a normalized SK expression value: deltaOD405/RLU
3) normalized SK expression values were background subtracted using the median of the 32 negative controls wells on the same plate and scaled using the median value of the 32 positive control wells located on two separate control plates in the same run.
B. IC50 values were calculated based on the normalized, scaled SK expression values using the Smart Fit strategy of Genedata Screener Condoseo (v6.0.1). IC50 values were extrapolated up to 1 log over the highest tested concentration.
PUBCHEM_ACTIVITY_SCORE:
Inactive compounds = 0
Active compounds = -10*Log(IC50)
PUBCHEM_ACTIVITY_OUTCOME:
Activity_Outcome = 1 (inactive)
IC50 > 1 log over the highest tested concentration
Activity_Outcome = 2 (active)
IC50 <= 1 log over the highest tested concentration
Result Definitions
Show more |
| TID | Name | Description | Histogram | Type | Unit | |
|---|---|---|---|---|---|---|
| Outcome | The BioAssay activity outcome | Outcome | ||||
| Score | The BioAssay activity ranking score |  | Integer | |||
| 1 | EC50 Qualifier | '>', '=', or '<' | String | |||
| 2 | EC50* | the concentration whereupon perceived activity reaches 50% of the maximum | | Float | μM | |
| 3 | EC50 Standard Error | the standard error for the calculated EC50 value | | Float | μM | |
| 4 | S0 | the fitted activity level at zero concentration | | Float | % | |
| 5 | SInf | the fitted activity level at infinite concentration | | Float | % | |
| 6 | Hill Slope | the slope at EC50 | | Float | ||
| 7 | # of Points Fit | the number of data points included in the plot | | Integer | ||
| 8 | Max. Activity | the maximum activity value observed | | Float | % | |
| 9 | Activity at 0.06uM (0.06μM**) | The average measured activity of all accepted replicates at the specified concentration | | Float | % | |
| 10 | Activity at 0.18uM (0.18μM**) | The average measured activity of all accepted replicates at the specified concentration | | Float | % | |
| 11 | Activity at 0.56uM (0.56μM**) | The average measured activity of all accepted replicates at the specified concentration | | Float | % | |
| 12 | Activity at 1.60uM (1.6μM**) | The average measured activity of all accepted replicates at the specified concentration | | Float | % | |
| 13 | Activity at 5.00uM (5μM**) | The average measured activity of all accepted replicates at the specified concentration | | Float | % | |
| 14 | Activity at 15.00uM (15μM**) | The average measured activity of all accepted replicates at the specified concentration | | Float | % |
* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1R03DA026214-01
Data Table (Concise)
PageFrom: